Aktie A2JMW5 ONCOLYTICS BIOTECH INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Oncolytics Biotech Inc. Nasdaq

Aktien

A2JMW5

CA6823108759

ONCY

Markt geschlossen - Nasdaq
Andere Börsenplätze
 22:00:00 28.06.2024 		% 5 Tage % 1. Jan.
0,99 USD -1,98 % Intraday Chart für Oncolytics Biotech Inc. -1,98 % -26,67 %
24.06. Oncolytics Biotech CEO Matt Coffey lässt sich aus medizinischen Gründen beurlauben MT
20.06. Oncolytics Biotech verabreicht ersten Patienten in Studie zur Pelareorep/FOLFIRINOX-Kombinationstherapie bei Bauchspeicheldrüsenkrebs CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Oncolytics Biotech Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
Oncolytics Biotech UP 1.9% In US Premarket Announces "Productive" FDA Type C Meeting on Metastatic Breast Cancer Program
Oncolytics Biotech Brief: Announcing Productive FDA Type C Meeting on its Metastatic Breast Cancer Program
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence
Oncolytics Biotech Brief: Announcing President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
Oncolytics Biotech Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX
Oncolytics Biotech Brief: Says Dosed First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting
Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2JMW5 Aktie
  4. A2JMW5 Aktie
  5. Nachrichten Oncolytics Biotech Inc.
  6. Andere Sprachen